Progress in clinical fibrinolysis

Fibrinolysis and Proteolysis

Volumn 11, Issue 2, 1997, Pages 67-84

  Emeis, J J ^a   Verheijen, J H ^a   Ronday, H K ^a   De Maat, M P M ^a   Brakman, P ^a  

^a TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPLASMIN; FIBRINOGEN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

BLOOD CLOT LYSIS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; FIBRIN FORMATION; FIBRINOLYSIS; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE; MOLECULAR BIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RHEUMATOID ARTHRITIS; SKIN DISEASE; THROMBOCYTE ACTIVATION;

EID: 0030723825     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80098-7     Document Type: Review

References (302)

1. Carmeliet P, Collen D. Evaluation of the plasminogen/plasmin system in transgenic mice. Fibrinolysis 1994; 8, suppl l : 269-276.
2. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995; 74: 429-436.
3. Carmeliet P, Collen D. Targeted gene manipulation and transfer of the plasminogen and coagulation systems in mice. Fibrinolysis 1996; 10: 195-213.
4. Carmeliet P, Collen D. Evaluation of the role of the fibrinolytic system in transgenic animals. In: van Hinsbergh V W M, ed. Vascular control of haemostasis. Victoria. Gordon and Breach Science Publishers: 1996:247-256.
5. Bachman F. The role of plasminogen activator inhibitor 1 (PAI1) in the clinical setting, including deep vein thrombosis. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton, CRC Press, 1995: 79-86.
6. Gelman S. General versus regional anesthesia for peripheral vascular surgery. Is the problem solved? Anesthesiology 1993; 79:415-418.
7. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis: an update. Fibrinolysis 1994; 8, suppl 1: 253-262.
8. Hamsten A, Eriksson P. Fibrinolysis and atherosclerosis. Baillière's Clin Haematol 1995; 8: 345-363.
9. Hamsten A, Eriksson, P, Karpe F, Silveira A. Relationships of thrombosis and fibrinolysis to atherosclerosis. Curr Opin Lipidol 1994; 5:382-389.
10. Haverkate F, Thompson S G, van de Loo J C. The relationship between hemostatic tests and cardiovascular risk factors in patients with angina pectoris. Ann Epidemiol 1992; 2: 521-524.
11. Juhan-Vague I, Alessi M C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost 1993; 70:138-143.
12. Juhan-Vague l, Alessi M-C, Declerck P J. Pathophysiology of fibrinolysis. Baillière's Clin Haematol 1995; 8: 329-343.
13. Juhan-Vague I, Alessi M C, Nalbone G. Fibrinolysis and atherothrombosis. Curr Opin Lipidol 1993; 4: 477-483.
14. Juhan-Vague I, Alessi M C, Vague P. Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 1996; 28: 371-380.
15. 5. Juhan-Vague I, Pyke S D M, Alessi M C, et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94: 20572063.
16. Lijnen H R, Collen D. Impaired fibrinolysis and the risk for coronary heart disease. Circulation 1996; 94: 2052-2054.
17. Prins M H, Hirsh J A. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Int Med 1991 ; 151: 1721 -1731.
18. Ridker P M. An epidemiological assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992; 3: 285-290.
19. Wilcox J N. Thrombotic mechanisms in atherosclerosis. Cor Art Dis 1994; 5:223-229.
20. Wiman B. Plasminogen activator inhibitor-1 (PAI-1) in plasma: its role in thrombotic disease. Thromb Haemost 1995; 74: 71-76.
21. de Maat M P M, de Bart A C W, Hennis B C, et al. Interindividual and intraindividual variability in plasma fibrinogen, tPA antigen, PAI activity and CRP in healthy young volunteers and patients with angina pectoris. Arterioscler Thromb Vase Biol 1996; 16: 1156-1162.
22. Eliasson M, Evrin P-E, Lundblad D, Asplund K, Ranby M. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis 1993; 7: 316-323.
23. Nguyen N D, Ghaddar H, Stinson V, et al. AR1C hemostasis study - IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995; 73: 256-260.
24. Jespersen J, Bertina R M, Haverkate F (eds). ECAT assay procedures. A manual of laboratory technique. Dordrecht: Kluwer Academic Publishers, 1992.
25. Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10, supp!2: 171-179.
26. Gaffney P J. Standards in fibrinolysis. Current status and future challenge. Thromb Haemost 1995: 74: 1389-1397.
27. de Bono D. Can coronary thrombolysis meet the challenge of primary angioplasty? Fibrinolysis 1996: 10: 137-142.
28. Lange R A, Hillis L D, Grines C L. Clinical debate. Should thrombolysis or primary angioplasty be the treatment of choice for acute myocardial infarction? New Engl J Med 1996; 335: 1311-1317.
29. Benedict C R, Refino C J, Keyt B A, Pakala R, Paoni N F, Thomas G R, Bennett W F. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92: 3032-3040.
30. Lijnen H R, Collen D. Staphylokinase, a fibrin-specific bacterial plasminogen activator. Fibrinolysis 1996; 10: 119-126.
31. Bode C, Runge M S, Smalling R W. The future of thrombolysis in the treatment of acute myocardial infarction. Eur Heart J 1996; 17, suppl E: 55-60.
32. NINDS-rt-PA stroke study group. Tissue plasminogen activator for acute ischaemic stroke. New Engl J Med 1995; 333: 15811587.
33. Brommer E J P, Emeis J J, Verheijen J H, Brakman P. Progress in clinical fibrinolysis. In: Poller L, ed. Recent advances in blood coagulation, Vol 7. London: Churchill Livingstone: 1997; 161182.
34. Brommer E J P, Dooijewaard G, Rijken D C, Kluft C, Emeis J J, Brakman P. Progress in clinical fibrinolysis. In: Poller L, ed. Recent advances in blood coagulation, Vol 6. London: Churchill Livingstone: 1993; 1-15.
35. Binder B R. Physiology and pathophysiology of the fibrinolytic system. Fibrinolysis 1995; 9, suppl 1: 3-8.
36. Declerk P J, Lijnen HR, Verstrecken M, Collen D. Role of a2~ antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma. Thromb Haemost 1991; 65: 394-398.
37. Lijnen H R, Collen D. Mechanisms of physiological fibrinolysis. Baillière's Clin Haematol 1995; 8: 277-290.
38. Rijken D C. Plasminogen activators and plasminogen activator inhibitors; biochemical aspects. Baillière's Clin Haematol 1995; 8:291-312.
39. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-276.
40. Beer J H, May H-P, Herren T, Haeberli A, Sträub P W. Whole blood clot lysis: enhanced by exposure to autologous but not to homologous plasma. Thromb Haemost 1994; 71: 622-626.
41. Redlitz A, Tan A K, Eaton D L, Plow E F. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 96: 2534-2538.
42. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-16608.
43. Broze G J, Higuchi D A. Coagulation-dependent inhibition of fibrinolysis: role of carboxypeptidase-U and the premature lysis of clots from hémophilie plasma. Blood 1996; 88: 3815-3823.
44. von dem Borne P A Kr, Meijers J C M, Bouma B N. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects flbrin clots from fibrinolysis. Blood 1995; 86: 3035-3042.
45. Fareed J, Francis J L (eds). Tissue factor and tissue factor pathway inhibitor. Blood Coagul Fibrinol 1995: 6, suppl ement 1.
46. Lupu C, Lupu F, Dennehy U, Kakkar V V, Scully M F. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells. Arterioscler Thromb Vase Biol 1995; 15: 2055-2062.
47. Emeis J J, van den Eijnden-Schrauwen Y, Kooistra T. Tissuetype plasminogen activator and the vessel wall: synthesis, storage and secretion. In: van Hinsbergh VWM (ed). Vascular control of haemostasis. Victoria: Gordon and Breach Science Publishers, 1996; 187-206.
48. Esmon C T. Anticoagulant properties of vascular cells: thrombomodulin and protein C activation pathway. In: van Hinsbergh VWM, ed. Vascular control of haemostasis. Victoria: Gordon and Breach Science Publishers, 1996: 9-37.
49. de Munk G W A, Groeneveld E, Rijken D C. Acceleration of the thrombin inactivation of single chain urokinase-type plasminogen activator (pro-urokinase) by thrombomodulin. J Clin Invest 1988; 88: 1680-1684.
50. Braat E A M, Nauland U, Dooijewaard G, Rijken D C. A sensitive bioimmunoassay for thrombin-cleaved two-chain urokinasetype plasminogen activator in human body fluids. Thromb Haemost 1996; 75: 908-914.
51. van den Eijnden-Schrauwen Y, Kooistra T, de Vries R E M, Emeis J J. Studies on the acute release of tissue-type plasminogen activator from human endothelial cells in vitro and in rats in vivo: evidence for a dynamic storage pool. Blood 1995; 85: 3510-3517.
52. Nieuwenhuizen W. Personal communication, 1996.
53. Sobel J H, Wu H Q, Canfield R E. The development of assays for the detection of fibrin(ogen)olysis based on COOH-terminal A alpha chain epitopes. Blood 1994; 84: 535-546.
54. Sakharov D V, Rijken D C. Superficial accumulation of plasminogen during plasma clot lysis. Circulation 1995; 92: 18831890.
55. Sakharov D V, Nagelkerke J F, Rijken D C. Rearrangement of the flbrin network and spatial distribution of fibrinolytic components during plasma clot lysis. J Biol Chem 1996; 271: 2133-2138.
56. Wu J-H, Siddiqui K, Diamond SL. Transport phenomena and clot dissolving therapy: an experimental investigation of diffusion-controlled and permeation-enhanced fibrinolysis. Thromb Haemost 1994; 72: 105-112.
57. Francis C W, Önundarson P T, Carstensen E L, et al. Enhancement of fibrinolysis in vitro by ultrasound. J Clin Invest 1992; 90: 2063-2068.
58. Lauer C G, Bürge R, Tang D B, et al. Effect of ultrasound on tissue-type plasminogen activator-induced thrombolysis. Circulation 1992; 86: 1257-1264.
59. Kashyap A, Blinc A, Marder V J, et al. Acceleration of fibrinolysis by ultrasound in a rabbit ear model of small vessel injury. Thromb Res 1994; 76: 475-485.
60. Blinc A, Francis C W. Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost 1996; 76: 481-491 .
61. Mashina S Y, Bashkov G V. Plasmin-induced endotheliumdependent vasodilatation versus fibrinolysis - two pathways of blood flow restoration in the thrombotically occluded vessels? Fibrinolysis 1994; 8, suppl 2: 113-115.
62. Husain S S. Fibrin affinity of urokinase-type plasminogen activator. Evidence that Zn2+ mediates strong and specific interaction of single-chain urokinase with fibrin. J Biol Chem 1993; 268: 8574-8579.
63. Brommer E J P, van Bockel J H. Composition and susceptibility to thrombolysis of human arterial thrombi and the influence of their age. Blood Coagul Fibrinol 1992; 3:717-725.
64. Dooijewaard G. The post-thrombolytic era: is it possible to prevent thrombosis by stimulating indigenous fibrinolysis. Fibrinolysis 1993; 7, suppl 1: 42-43.
65. de Boer A, Kluft C, Gerloff J, et al. Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thromb Haemostas 1993; 70: 320-325.
66. Emeis J J. Normal and abnormal endothelial release of tissue-type plasminogen activator. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 55-64.
67. Jern C, Selin L, Jern S. In vivo release of tissue-type plasminogen activator across the human forearm during mental stress. Thromb Haemost 1994; 72: 285-291.
68. Jern S, Selin L, Bergbrant A, Jern C. Release of tissue-type plasminogen activator in response to muscarinic receptor stimulation in human forearm. Thromb Haemostas 1994; 72: 588-594.
69. Bashkov G V, Sergeev IY, Medvedeva N A. Role of sympathetic cholinergic pathway in the neurogenous control of tissue-type plasminogen activator release into the blood. Blood Coagul Fibrinol 1993; 4: 993-998.
70. Chandler W L, Veith R C, Fellingham G W et al. Fibrinolytic response during exercise and epinephrine infusion in the same subjects. J Am Coll Cardiol 1992; 19: 1412-1420.
71. Chandler W L, Levy W C, Veith R C, Stratton J R. A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training. Blood 1993; 81: 3293-3302.
72. Chandler W L, Levy W C, Stratton J R. The circulatory regulation of t-PA and uPA secretion, clearance, and inhibition during exercise and during the infusion of isoproterenol and phenylephrine. Circulation 1995; 92: 2984-2994.
73. Kooistra T, Emeis J J. Agents which increase synthesis and release of tissue-type plasminogen activator. In: Bachmann F ed. Handbook of Experimental Pharmacology. New York: Springer Verlag, 1997 (in press)
74. Wall U, Jern C, Jern S. Stimulated reelase of tissue-type plasminogen activator across the human forearm in response to desmopressin: evidence for a very large releasable pool (abstract). Fibrinolysis 1996; 10, suppl 3: 92.
75. Hirsch AT, Dzau VJ, Majzoub JA, Creager MA. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. J Clin Invest 1989: 84: 418-426.
76. Levi M, Roem D, Kamp A M, et al. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69: 141-146.
77. Shigekiyo T, Ohshima T, Oka H, Tomonari A, Azuma H, Saito S. Congenital histidine-rich glycoprotein deficiency. Thromb Haemostas 1993; 70: 263-265.
78. Hennis B C. Histidine-rich glycoprotein and thrombosis. Thesis, Leiden, 1995.
79. Boomsma DI, Hennis B C, van Wees A G M, Frants R R, Kluft C. A parent-twin study of plasma levels of histidine-rich glycoprotein. Thromb Haemost 1993; 70: 848-851.
80. Ridker P M, Gaboury C L, Conlin P R, et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
81. Brown N J, Vaughan D E. The renin-angiotensin and fibrinolytic systems. Co-conspirators in the pathogenesis of ischaemic cardiovascular disease. Trends Cardiovasc Med 1996; 6: 239-243.
82. Vaughan D E, Lazos S A, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. J Clin Invest 1995; 95: 995-1001.
83. Wright R A, Flapan A D, Alberti K G, Ludlam C A, Fox K A. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction. J Am Coll Cardiol 1994; 24: 67-73.
84. Jansson J H, Boman K, Nilsson T K. Enalapril-related changes in the fibrinolytic system in survivors of myocardial infarction. Eur J Clin Pharmacol 1993; 44: 485-488.
85. Vaughan D E, Rouleau J-L, Pfeffer M A. Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 1995; 16: 31-36.
86. Emeis J J, Tranquille N. On the role of bradykinin in secretion from vascular endothelial cells. Agents Actions 1992; 38, suppl II: 285-291.
87. Charlton P A, Faint R W, Bent F, et al. Evaluation of a low molecular weight modulator of human plasminogen activator inhibitor-1 activity. Thromb Haemost 1996; 75: 808-815.
88. Eitzman D T, Fay W P, Lawrence D A, et al. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-2420.
89. Fearns C, Samad F, Loskutoff D ]. Synthesis and localization of PAI-1 in the vessel wall. In: van Hinsbergh V W M, ed. Vascular control of haemostasis. Victoria: Gordon and Breach Science Publishers, 1996: 207-226.
90. Kruithof EKO, Baker MS, Bunn CL. Biological and clinical aspects of plasminogen activator inhibitor type 2. Blood 1995; 86: 4007-4024.
91. Green F, Humphries S. Genetic determinants of arterial thrombosis. Baillières Clin Haematol 1994; 7: 675-692.
92. Ludwig M, Wohn K-D, Schleuning W-D, Olek K. Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event. Hum Genet 1992; 88: 388-392.
93. van der Bom J G, Bots M L, Haverkate F, Grobbee D E, Kluft C. Fibrinolytic capacity and risk of myocardial infarction. Fibrinolysis 1996; 10, suppl 2: 9-12.
94. van der Bom J G, de Knijff P, Bots M L, Haverkate F, Hofman A, Kluft C, Grobbee D E. Polymorphism of the blood clot lysis enzyme tissue-type plasminogen activator is associated with myocardial infarction (abstract). Fibrinolysis 1996; 10 suppl 1: 27-28.
95. lacoviello L, Di Castelnuovo A, de Knijff P, D'Orazio A, Amore C, Kluft C, Donati M B. Alu-repeat polymorphism in the tissue-type plasminogen activator (t-PA) gene, t-PA levels and risk of familial myocardial infarction (MI). Fibrinolysis 1996; 10, suppl 2: 13-16.
96. van den Eijnden-Schrauwen Y, Lakenberg N, Emeis J J, de Knijff P. Alu-repeat polymorphism in the tissue-type plasminogen activator gene does not affect basal endothelial t-PA synthesis (letter to the editor). Thromb Haemost 1995; 74: 1202
97. Klinger K, Winqvist R, Riccio A, et al. Plasminogen activator inhibitor type-1 gene is located at region q21,3-q22 of chromosome 7 and genetically linked with cystic fibrosis. Proc Natl Acad Sei USA 1987; 84: 8548-8552.
98. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1991; 11: 183-190.
99. Dawson S, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promotor of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
100. Mansfield M W, Stickland M H, Carter A M, Grant P J. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-736.
101. Panahloo A, Mohamed-Ali V, Lane A, et al. Determinants of plasminogen activator inhibitor 1 activity in treated N1DDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42.
102. Eriksson P, Kallin B, van't Hooft F M, Bavenholm P, Hamsten A. Allele-specific increase in basal PAI-1 transcription associated with myocardial infarction. Proc Natl Acad Sei USA 1995; 92: 1851-1855.
103. Mansfield M W, Stickland M H, Grant P J. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non-insulin-dependent diabetes. Thromb Haemost 1995; 74: 1032-1034.
104. Ye S, Green F R, Scarabin P Y, et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-841.
105. Ridker P M, Hennekens C H, Lindpaintner K, Stampfer M J, Miletich J P. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor (PAI-1) gene in a large cohort of US men. Circulation 1997; 95: 59-62.
106. Freedman J E, Loscalzo J. Platelets and fibrinolysis/thrombolysis. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 65-69.
107. Fay W P, Eitzman D T, Shapiro A D, Madison E L, Ginsburg D. Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood 1994; 83: 351-356.
108. Orchard M A, Goodchild C S, Prentice C R M, Davies J A, Benoit S E. Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. Br J Haematol 1993; 85: 533-541.
109. Robbie L A, Booth N A, Croll A M, Bennett B. The roles of alpha2antiplasmin and plasminogen activator inhibitor 1 (PAI-1) in the inhibition of clot lysis. Thromb Haemost 1993; 70: 301-306.
110. Chung H I, Burman J F, Balogun B A, Lincoln J C R, Pepper J R. Elevated fibrinolysis in cardiopulmonary bypass is factor XII dependent. Fibrinolysis 1994; 8, suppl 2: 84-88.
111. Gurewich V, Johnstone M, Loza J P, Pannell R. Pro-urokinase and prekallikrein are both associated with platelets. Implications for the intrinsic pathway of fibrinolysis and for therapeutic thrombolysis. FEES Lett 1993; 318: 317-321.
112. Kluft C, Verheijen J H (eds). Lifestyle and fibrinolysis. Fibrinolysis 1990; 4, suppl 2: 47-161.
113. Kluft C, Verheijen J H (eds). Intervention in fibrinolysis. Fibrinolysis 1994; 8, suppl 2: 1-165.
114. Hendriks H F, Veenstra J, Velthuis-te Wierik E J, Schaafsma G, Kluft C. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. Br Med J 1994; 308: 1003-1006.
115. Veenstra J, Kluft C, van de Pol H, Dooijewaard G, Schaafsma G. Acute effects of moderate alcohol consumption on fibrinolytic factors in healthy middle-aged men. Fibrinolysis 1993; 7: 177182.
116. Ridker P M, Vaughan D E, Stampfer M J, Glynn R J, Hennekens C H. Association of moderate alcohol consumption and plasma concentration of endogenous tissue-type plasminogen activator. J Am Med Ass 1994; 272: 929-933.
117. Lee A J, Flanagan P A, Rumley A, Fowkes F G R, Löwe G D O. Relationship between alcohol intake and tissue plasminogen activator antigen and other haemostatic factors in the general population. Fibrinolysis 1995; 8: 49-54.
118. Hellsten G, Boman K, Saarem K, Hallmans G, Nilsson T K. Effects on fibrinolytic activity of corn oil and a fish oil preparation enriched with omega-3-polyunsaturated fatty acids in a long-term study. Curr Med Res Opin 1993; 13: 133-139.
119. Boberg M, Pollare T, Siegbahn A, Vessby B. suppl ementation with n-3 fatty acids reduces triglycérides but increases PAI-1 in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 1992; 22: 645-650.
120. Eritsland J, Seljeflot I, Abdelmoor M, Arnesen H. Long-term influence of omega-3 fatty acids on fibrinolysis, fibrinogen, and serum lipids. Fibrinolysis 1994; 8: 120-125.
121. Fumeron F, Brigant L, Ollivier V, et al. n-3 polyunsaturated fatty acids raise low-density lipoproteins, high-density lipoprotein 2, and plasminogen activator inhibitor in healthy young men. AmJClinNutr 1991; 54: 118-122.
122. Emeis J J, van Houwelingen A C, van den Hoogen C M, Hornstra G. A moderate fish intake increases plasminogen activator inhibitor type-1 in human volunteers. Blood 1989; 74: 233-237.
123. Haglund O, Hamfelt A, Hambraeus L, Saldeen T. Effects offish oil suppl emented with pyridoxine and folic acid on homocysteine, atherogenic index, fibrinogen and plasminogen activator inhibitor-1 in man. Nutr Res 1993; 13: 1351-1365.
124. M011er J M, Svaneborg N, Lervang H H, et al. The acute effect of a single very high dose of N-3 fatty acids on coagulation and fibrinolysis. Thromb Res 1992; 67: 569-577.
125. Marckmann P, Sandström B, Jespersen J. Fasting blood coagulation and fibrinolysis of young adults unchanged by reduction in dietary fat content. Arterioscler Thromb 1992; 12:201-205.
126. Marckmann P, Sandström B, Jespersen J. Favorable long-term effect of a low-fat/high-fiber diet on human blood coagulation and fibrinolysis. Arterioscler Thromb 1993; 13: 505-511.
127. Marckmann P, Sandström B, Jespersen J. Low-fat, high-fiber diet favorably affects several independent risk markers of ischémie heart disease: observations on blood lipids, coagulation, and fibrinolysis from a trial of middle-aged Danes. Am J Clin Nutr 1994; 59: 935-939.
128. Marckman P. Diet, blood coagulation and fibrinolysis. Dan Med Bull 1995; 42: 410-425.
129. Marckman P, Jespersen J. Introduction to diet and endogenous fibrinolysis. Fibrinolysis 1994; 8, suppl 2: 37-40.
130. Sundell I B, Ranby M. Oat husk fiber decreases plasminogen activator inhibitor type 1 activity. Haemostasis 1993; 23: 45-50.
131. Guzic B, Sundell I B, Keber I, Keber D. The effect of oat husk suppl ementation in diet on plasminogen activator inhibitor type 1 in diabetic survivors of myocardial infarction. Fibrinolysis 1994; 8, suppl 2: 44-46.
132. Nilsson T K, Boman K, Zhang J-X, Hallmans G. Diet and fibrinolysis, with special reference to fiber intake. In: GlasGreenwalt P, ed. Fibrinolysis in disease, Vol 2. Boca Raton: CRC Press, 1995: 110-114.
133. Sylvan A, Rutegard J N, Janunger K G, Sjolund B, Nilsson T K. Normal plasminogen activator inhibitor levels at long-term follow-up after jejuno-ileal bypass surgery in morbidly obese individuals. Metabolism 1992; 41: 1370-1372.
134. Folsom AR, Qamhieh HT, Wing RR, et al. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic risk factors in moderately overweight adults. Arterioscler Thromb 1993; 13: 162-169.
135. Velthuis-te Wierik E J M, Meijer P, Kluft C, van den Berg H. Beneficial effect of a moderate energy-restricted diet on fibrinolytic factors in non-obese men. Metabolism 1995; 44: 1548-1552.
136. Calles-Escandon J, Bailor D, Harvey-Berino J, et al. Amelioration of the inhibition of fibrinolysis by moderate energy intake restriction. Am J Clin Nutr 1996; 64: 7-11.
137. Winther K, Svendsen O L, Hassager C, Christiansen C, Nielsen J D. Fibrinolysis in overweight postmenopausal women - effect of dieting and exercise. Blood Coag Fibrinol 1996; 7: 409-410.
138. Palareti G, Legnani C, Poggi M, et al. Prolonged very low calorie diet in obese subjects reduces factor VTI and PAI but not fibrinogen levels. Fibrinolysis 1994; 8: 16-21.
139. Willich S N, Lewis M, Löwel H. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993; 329: 16841690.
140. de Geus E J, Kluft C, de Bart A C, van Doornen L J. Effects of exercise training on plasminogen activator inhibitor activity. Med Sei Sports Exerc 1992; 24: 1210-1219.
141. van den Burg P J. The effects of physical exercise and training on blood coagulation and fibrmolysis. Thesis, Utrecht, 1994.
142. van den Burg P J, Dooijewaard G, van Vliet M, et al. Differences in u-PA and t-PA increase during acute exercise; relation with exercise parameters. Thromb Haemost 1994; 71: 236-239.
143. van den Burg P J M, Hospers J E H, van Vliet M, et al. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost 1995; 74: 1457-1464.
144. Huisveld IA, van den Burg P J M, van Vliet M, Hospers J E H, Mosterd W L. The urokinase-type, rather than the tissue-type plasminogen system is influenced by regular physical training. Fibrinolysis 1994; 8, suppl 1:13.
145. Suzuki T, Yamauchi K, Yamada Y, et al. Blood coagulability and fibrinolytic activity before and after physical training during the recovery phase of acute myocardial infarction. Clin Cardiol 1992; 15:358-364.
146. Boman K, Hellsten G, Bruce A, Hallmans G, Nilsson T K. Endurance physical activity, diet and fibrinolysis. Atherosclerosis 1994; 106: 65-74.
147. Rankinen T, Rauramaa R, Väisänen S, Halonen P, Penttilä l M. Blood coagulation and fibrinolytic factors are unchanged by aerobic exercise or fat modified diet. Randomized clinical trial in middle-aged men. Fibrinoysis 1994; 8: 48-53.
148. Juhan-Vague I, Thompson S G, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome. A study of 1500 patients with angina pectoris. Arterioscler Thromb 1993; 13: 1865-1873.
149. Reaven G M. Syndrome X: 6 years later. J Intern Med 1994; 236, suppl 736: 13-22.
150. Nordt T K, Klassen K J, Schneider D J, Sobel B E. Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 1993; 13: 1822-1828.
151. Sawey M S, Eoskutoff D J. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. J Clin Invest 1991; 88: 1346-1353.
152. Eundgren C H, Brown S E, Nordt T K, Sobel B E, Fujii S. Elaboration of type-1 plasminogen activator inhibitor from adipocytes. A potential pathogenetic link between obesity and cardiovascular disease. Circulation 1996; 93: 106-110.
153. Samad F, Yamamoto K, Loskutoff D J. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. J Clin Invest 1996; 97: 37-46.
154. Shimomura I, Funahashi T, Takahashi M, et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nature Medicine 1996; 2: 800-803.
155. Nagi D K, Knowler W C, Hanson R E, Mohamed Ali V, Yudkin J S. Plasminogen activator inhibitor (PAI-1) and non-insulindependent diabetes in Pima Indians, South Asians and Europeans. Thromb Haemostas 1996; 76: 921-927.
156. Nagi D K, Hendra T J, Ryle A J, et al. The relationship of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulindependent) diabetic subjects. Diabetologia 1990; 33: 532-537.
157. Bavenholm P, Proudler A, Silveira A, et al. Relationships of insulin and intact and split proinsulin to haemostatic function in young men with and without coronary artery disease. Thromb Haemost 1995; 73: 568-575.
158. Gray RP, Mohamed-Ali V, Patterson DEH, Yudkin JS. Determinants of plasminogen activator inhibitor-1 activity in survivors of myocardial infarction. Thromb Haemost 1995; 73: 261-267.
159. Jain S K, Nagi D K, Slavin B M, Lumb P J, Yudkin J S. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control. Diabet Med 1993; 10:27-32.
160. Nagi D K, Yudkin J S. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. Diabetes Care 1993; 16: 621-629.
161. Gough S C, Rice P J, McCormack L, Chapman C, Grant P J. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 1993; 10: 638-642.
162. Cortellaro M, Cofrancesco E, Boschetti C, et al. Association of increased fibrin turnover and defective fibrinolytic capacity with leg atherosclerosis. Thromb Haemost 1994; 72: 292-296.
163. Smith F B, Löwe G D, Fowkes F G, et al. Smoking, haemostatic factors and lipid peroxides in a population case control study of peripheral arterial disease. Atherosclerosis 1993; 102: 155-162.
164. Johansson J, Egberg N, Johnsson H, Carlson L A. Serum lipoproteins and hemostatic function in intermittent claudication. Arterioscler Thromb 1993; 13: 1441-1448.
165. Oudenhoven L F I J, Brommer E J P, Aronson D C, et al. Impaired fibrinolysis in young adults with arterial occlusive disease: the relationship with hyperinsulinism and smoking. Fibrinolysis 1994; 8: 263-269.
166. Potter van Loon B J, Kluft C, Radder J K, Blankenstein M A, Meinders A E. The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulinresistance. Metabolism 1993; 42: 945-949.
167. Mykkänen L, Rönnemaa T, Marniemi J, et al. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 1994; 14: 1264-1271.
168. Urano T, Kojima Y, Takahashi M, et al. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Jpn J Physiol 1993; 43: 221-228.
169. Wieczorek I, Pell ACH, Mclver B, et al. Coagulation and fibrinolytic systems in type 1 diabetes: effects of venous occlusion and insulin-induced hypoglycaemia. Clin Sei 1993; 84: 79-86.
170. Caron P, Bennet A, Camare R, et al. Plasminogen activator inhibitor in plasma is related to testosterone in men. Metabolism 1989; 38: 1010-1015.
171. Yang X-C, Jing T-Y, Resnick L M, Phillips G B. Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 1993; 13: 467-471.
172. Glueck C j, Glueck H I, Stroop J, et al. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men. J lab Clin Med 1993; 122: 412-420.
173. Phillips G B, Pinkernell B H, Jing T-Y. The association of hypotestosteronemia with coronary artery disease in men. Arterioscler Thromb 1994; 14: 701-706.
174. De Pergola G, De Mitrio V, Cignarelli M, et al. Influence of free testosterone on antigen levels of plasminogen activator inhibitor-1 in premenopausal women with central obesity. Metabolism 1992; 41: 131-134.
175. Johansson J-O, Landin K, Tengborn L, Rosen T, Bengtsson B-A. High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults. Arterioscler Thromb 1994; 14:434-437.
176. van Hinsbergh V W M. Effects of TNF-a on endothelial control of haemostasis. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 143-151.
177. van der Poll T, Levi M, van Deventer S J. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83: 446-451.
178. van der Poll T, ten Gate H, van Deventer S J H, ten Cate J W. Pathogenesis of the altered vascular hemostasis properties in sepsis: in vivo studies. In: van Hinsbergh VWM (ed). Vascular control of haemostasis. Victoria: Gordon and Breach Science Publishers, 1996:281-308.
179. van der Poll T, Levi M, Hack C E, et al. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees. J Exp Med 1994; 179: 12531259.
180. Mestries J-C, Kruithof EKO, Gascon M-P, Herodin F, Agay D, Ythier A. In
181. Levi M, ten Gate H, Bauer K A, et al. Inhibition of endotoxininduced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-120.
182. Biemond B J, Levi M, ten Gate H, et al. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor Vll/VIIa. Thromb Haemost 1995; 73: 223-230.
183. Corssmit E P M, Levi M, Hack C E, ten Gate J W, Sauerwein H P, Romijn J A. Fibrinolytic response to interferon-a in healthy human subjects. Thromb Haemost 1996; 75: 113-117.
184. Gluszko P, Undas A, Amenta S, Szczeklik A, Schmaier AH. Administration of gamma Interferon in human subjects decreases plasminogen activation and fibrinolysis without influencing Cl inhibitor. J Lab Clin Med 1994; 123:232-240.
185. Menzel D, Levi M, Dooijewaard G, Peters M, ten Gate J W. Impaired fibrinolysis in the hemolytic-uremic syndrome of childhood. Ann Hematol 1994; 68: 43-48.
186. Bergstein J M, Riley M, Bang N U. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic urémie syndrome. New Engl J Med 1992; 327: 755759.
187. Brommer E J P, van den Wall Bake AWL, Dooijewaard G, et al. Blood fibrinolysis and the response to desmopressin in glomerulonephritis. Thromb Haemost 1994; 71: 19-25.
188. van de Kar N C A J, van Hinsbergh V W M, Brommer E J P, Monnens L A H. The fibrinolytic system in the haemolytic uremic syndrome: in vivo and in vitro studies. Pediatr Res 1994; 36: 257-264.
189. Brommer E J P. Fibrinolysis and inflammation. In: GlasGreenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 110-116.
190. Parkkinen J. Mechanisms leading to the activation of the fibrinolytic system in septicemia. In: Glas-Greenwalt P (ed). Fibrinolysis in disease, vol 1. Boca Raton, CRC Press, 1995; 126-129.
191. Philippe J, Offner F, Baele G, Leroux-Roels G. Prognostic markers in septic shock. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 124-125.
192. Hamilton J A, Campbell I K, WotjaJ, Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann NY Acad Sei 1991; 667:87-100.
193. Martel-Pelletier], Faure M P, McCollum R, Mineau F, Cloutier J M. Plasmin, plasminogen activators and inhibitors in human osteoarthritic cartilage. J Rheumatol 1991; 18: 1863-1871.
194. Brommer E J P, Dooijewaard G, Dijkmans BAC, Breedveld F C. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992; 51: 965-968.
195. Ronday H K, Smits H H, van Muijen G N P, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and noninflammatory joint disease. Br J Rheumatol 1996; 35: 416-423.
196. Busso N, Péclat V, So A, Sappino A-P. Plasminogen activation in synovial tissues: Differences between normal, osteoarthritis and rheumatoid arthritis joints. Arthr Rheum 1996; 39, suppl 9: 1026.
197. Gonzalez-Gronow M, Gawdi G, Pizzo S V. Characterization of the plasminogen receptor of normal and rheumatoid arthritis human synovial fibroblasts. J Biol Chem 1994; 269: 4360-4366.
198. Kummer J A, Abbink J J, de Boer J P, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint disease. Arthr Rheum 1992; 35: 884-893.
199. De Bart A C W, Quax P H A, Löwik C W G M, Verheijen J H. Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator mediated extracellular matrix degradation in human osteosarcoma cell line MG 63 by interleukin-1 alpha. J Bone Miner Res 1995; 10: 1374-1384.
200. Ronday H K, Smits H H, Quax P H A et al. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997, in press.
201. Leloup G, Délaisse J M, Vaes G. Relationship of the plasminogen activator/plasmin cascade to osteoclast invasion and mineral résorption in explanted fetal metatarsal bones. J Bone Miner Res 1994; 9: 891-902.
202. Anderson G I, Allan E H, Zhou H, Heersche J N M, Martin T J. Osteoclasts activated by lowered pH express urokinase receptor message and induce greater plasminogen activation. J Bone Miner Res 1995; 10, suppl 1 : S284.
203. Hoekman K, Löwik C W G M, van de Ruit M, et al. The effect of tissue-type-plasminogen activator (t-PA) on osteoclastic résorption in embryonic mouse long bone explants: a possible rôle for the growth factor domain of t-PA. Bone Miner 1992; 17: 1-13.
204. Collier S, Ghosh P. The role of plasminogen in interleukin-1 mediated cartilage degradation. J Rheumatol 1988; 15: 11291137.
205. Campbell I K, Piccolli D S, Butler D M, Singleton D K, Hamilton J A. Recombinant human interleukin-1 stimulates human articular cartilage to undergo résorption and human chondrocytes to produce both tissue and urokinase-type plasminogen activator. Biochem Biophys Acta 1989; 976: 183-194.
206. Murphy G, Ward R, Gavrilovic J, Atkinson S. Physiological mechanisms for metalloproteinase activation. Matrix 1992; suppl : 224-230.
207. Keski-Oja J, Lohi J, Tuutila A, Tryggvason K, Vartio T. Proteolytic processing of the 72,000 Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res 1992; 202: 471-476.
208. Fosang A J, Neame P J, Last K, et al. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases and cathepsin B. J Biol Chem 1992; 267: 19470-19474.
209. Kobayashi H, Schmitt M, Goretzki L, et al. Cathespin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (u-PA).JBiol Chem 1991; 266: 5147-5152.
210. Stevens P, Scott R W, Shatzen E M. Recombinant human protease nexin-1 prevents articular cartilage degradation in the rabbit. In: Joint destruction in arthritis and osteoarthritis. Basel: Birkhäuser Verlag, 1993: 173-176.
211. Nilsson I M. Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol 1979; 33, suppl 14: 41-47.
212. Butler M, Colombo C, Hickman L, et al. A new model of osteoarthritis in rabbits. III. Evaluation of anti-osteoarthritic effects of selected drugs administered intra-articularly. Arthr Rheum 1983; 26: 1380-1386.
213. Vignon E, Mathieu P, Gejui J, et al. Study of an inhibitor of plasminogen activator (tranexamic acid) in the treatment of experimental osteoarthritis. J Rheumatol 1991; 18, suppl 27: 131-133.
214. Ronday H K, Te Koppele J M, Greenwald R A, et al. Tranexamic acid, an inhibitor of plasminogen activation, reduces urinary crosslink excretion in experimental and rheumatoid arthritis (abstract). Arthrt Rheum 1996; 39, suppl 9: 1541.
215. Achbarou A, Kaiser S, Tremblay G, et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res 1994; 54: 2372-2377.
216. Delbaldo C, Masouye I, Saurai J H, Vassalli J D, Sappino A P. Plasminogen activation in melanocytic neoplasia. Cancer Res 1994; 54: 4547-4552.
217. de Vries T J, Quax P H A, Denijn M, et al. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Amer J Pathol 1994; 144: 70-81.
218. de Vries T J, Mooy C M, Vanbalken M R, et al. Components of the plasminogen activation system in uveal melanoma - a clinico-pathological study. J Pathol 1995; 175: 59-67.
219. Gladson C L, Pijuanthompson V, Olman M A et al. Up-regulation of urokinase and urokinase receptor genes in malignant astrocytoma. Am J Path 1995; 146: 1150-1160.
220. Gleeson N C, Gonsalves R, Bonnar J. Plasminogen activator inhibitors in endometrial adenocarcinoma. Cancer 1993; 72: 1670-1672.
221. Gleeson N C, Buggy F, Sheppard B L, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Eur J Gynaecol Oncol 1993; 14: 369-373.
222. Ito Y, Takeda T, Kobayashi T, et al. Plasminogen activation system is active even in thyroid tumors; an immunohistochemical study. Anticancer Res 1996; 16: 81-89.
223. Landau B J, Kwaan H C, Verrusio E N, Brem S S. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors. Cancer Res 1994; 54: 1105-1108.
224. Parolini S, Flagiello D, Cinquetti A, et al. Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. Br J Cancer 1996; 74: 1168-1174.
225. Rao J S, Rayford A, Morantz R A, Festoff B W, Sawaya R. Increased levels of plasminogen activator inhibitor-1 (PAI-1) in human brain tumors. J Neuro-oncol 1993 ; 17:215-221.
226. Schmalfeldt B, Kühn W, Reuning U et al. Primary tumor and metastasis in ovarian cancer differ in their content of urokinase-type plasminogen activator, its receptor, and inhibitors types 1 and 2. Can Res 1995; 55: 3958-3963.
227. Sier C F M, Verspaget H W, Griffioen G, et al. Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. Gut 1993; 34: 80-85.
228. Spiers E M, Lazarus G S, Lyonsgiordano B. Expression of plasminogen activators in basal cell carcinoma. J Pathology 1996; 178:290-296.
229. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator in human astrocytomas in vivo. Cancer Res 1994; 54: 3656-3661.
230. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas. Cancer Res 1994; 54: 5016-5020.
231. Sawaya R, Yamamoto M, Ramo O J et al. Plasminogen activator inhibitor-1 in brain tumors: relation to malignancy and necrosis. Neurosur 1995; 36: 375-380.
232. Wagner S N, Atkinson M J, Thanner S, Schmitt M, Wilhelm O, Rotter M, Hofler H. Type-1 plasminogen activator inhibitor in renal cell carcinoma. J Pathology 1996; 179: 95-99.
233. Yamamoto M, Sawaya R, Mohanam S, et al. Expression and cellular localization of messenger RNA for plasminogen activator inhibitor type 1 in human astrocytomas in vivo. Cancer Res 1994a; 54: 3329-3332.
234. Bianchi E, Cohen R L, Thor A T, et al. The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 1994; 54: 861-866.
235. de Vries T J, Ruiter D J, Weidle U H, Vanmuijen G N P. Localization of the components of the plasminogen activation system in cutaneous melanocytic lesions - a minireview. Fibrinolysis 1996; 10: 91-94.
236. Heiss M M, Allgayer H, Gruetzner K U et al. Individual development and uPA-receptor expression of disseminated tumor cells in bone marrow: a reference to early systemic disease in solid cancer. Nature Med 1995; 1: 1035-1039.
237. Hewin D G, Savage P B, Alderson D, Vipond M N. Plasminogen activators in oesophageal carcinoma. Brit J Surg 1996; 83: 1152-1155.
238. Buo L, Meling G I, Karlsrud T S, Johansen H T, Aasen A O. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Human Path 1995; 26: 1133-1138.
239. Costantini V, Sidonl A, Deveglia R et al. Comvined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer 1996; 77: 1079-1088.
240. Maeda K, Chung Y S, Sawada T et al. Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma. Int J Oncology 1996; 8: 499-503.
241. Mulcahy H E, Duffy M J, Gibbons D, et al. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet 1994; 344: 583-584.
242. Vanveldhuizen P J, Sadasivan R, Cherian R, Wyatt A. Urokinase-type plasminogen activator expression in human prostate carcinomas. AJMed Scie 1996; 312: 8-11.
243. Sier C F M, Vloedgraven H J M, Ganesh S, et al. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994; 107: 1449-1456.
244. Hofmann R, Lehmer A, Härtung R, Robrecht C, Buresch M, Grothe F. Prognostic value of urokinase plasminogen activator and plasminogen activator inhibitor-1 in renal cell cancer. J Urology 1996; 155: 858-862.
245. Dano A, Behrendt N, Brunner N, et al. The urokinase receptor protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994; 8: 198-203.
246. van Roozendaal C E P, Klijn J G M, Sieuwerts A M, HenzenLogmans SC, Foekens JA. Role of urokinase plasminogen activator in human breast cancer: active involvement of stromal fibroblasts. Fibrinolysis 1996; 10: 79-83.
247. Deng G, Curriden S A, Wang S J, Rosenberg S, Loskutoff D J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 1996; 134: 1563-1571.
248. Stefansson S, Lawrence D A. The serpin PAI-1 inhibits cell migration by blocking integrin cx 3 binding to vitronectin. Nature 1996; 383: 44-443.
249. Bouchet C, Spyratos F, Martin P M, et al. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Brit J Cancer 1994; 69: 398-405.
250. Duffy M J, Reilly D, Mcdermott E, et al. Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer 1994; 74: 2276-2280.
251. Duffy M J, Duggan C, Maguire T, et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme & Protein 1996; 49: 85-93.
252. Foekens J A, Schmitt M, van Putten W L J, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992; 52: 6101-6105.
253. Foekens J A, Schmitt M, van Putten W L J, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J ClinOncol 1994; 12: 1648-1658.
254. Grondahl-Hansen J, Christensen I J, Rosenquist C, et al. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 1993; 53: 2513-2521.
255. Jänicke F, Schmitt M, Fache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Research Treatment 1993; 24: 195-208.
256. Ganesh S, Sier C F M, Heerding M M, et al. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-402.
257. Ganesh S, Sier C F, Griffioen G, et al. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res 1994; 54: 4065-4071.
258. Ganesh S, Sier C F M, Heerding M M, et al. Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer 1996; 77: 1035-1043.
259. Hasui Y, Marutsuka K, Nishi S, et al. The content of urokinase-type plasminogen activator and tumor recurrence in superficial bladder cancer. J Urology 1994; 151: 16-19.
260. Heiss M M, Babic R, Allgayer H, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol 1995; 13: 2084-2093.
261. Ito H, Yonemura Y, Fujita H, et al. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer. Virchows Archiv 1996; 427: 487-496.
262. Kobayashi H, Fujishiro S, Terao T. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Cancer Res 1994; 54: 6539-6548.
263. Nekarda H, Siewert J R, Schmitt M, Ulm K. Tumour-associated proteolytic factor-uPA and factor-PAI-1 and survival in totally resected gastric cancer. Lancet 1994; 343:117.
264. Nekarda H, Schmitt M, Ulm K, et al. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 1994; 54: 2900-2907.
265. Noguchitakino M, Endo Y, Yonemure Y, Sasaki T. Relationship between expression of plasminogen activator system and metastatic ability in human cancers. Int J Oncology 1996; 8: 97-105.
266. Pedersen H, Grøndahl-Hansen J, Francis D, et al. Urokinase and plasminogen activator inhibitor type-1 in pulmonary adenocarcinoma. Cancer Res 1994; 54: 120-123.
267. Pedersen H, Brunner N, Francis D, et al. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 1994; 54: 4671-4675.
268. Sato T, Nishimura G, Yonemura Y, et al. Association of immunohistochemical detection of urokinase-type plasminogen activator with metastasis and prognosis in colorectal cancer. Oncology 1995; 52: 347-352.
269. Verspaget H W, Sier C F M, Ganesh S, Griffioen G, Lamers C B H W. Prognostic value of plasminogen activator and their inhibitors in colorectal cancer. Eur J Cane 1995; 31A: 11051109.
270. Yonemura Y, Mojima N, Kaji M, et al. E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 1995; 76: 941-953.
271. Foekens J A, Buessecker F, Peters H, et al. Plasminogen activator inhibitor-2: prognostic relevance in 1012 patients with primary breast cancer. Cancer Res 1995; 55: 1423-1427.
272. Ishikawa N, Enod Y, Sasaki T. Inverse correlation between mRNA expression of plasminogen activator inhibitor-2 and lymph node metastasis in human breast cancer. Japanese J Cane Res 1996; 87: 480-487.
273. 73. Foekens J A, Look M P, Peters H A, Vanputten W L J, Portengen H, Klijn J G M. Urokinase-type plasminogen activator and its inhibitor PAI-1 : predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Nat Cancer Inst 1995; 87: 751-756.
274. Brommer E J P, van den Wall Bake A W, Dooijewaard G, et al. Blood fibrinolysis and the response to desmopressin in glomerulonephritis. Thromb Haemost 1994; 71: 19-25.
275. Hong S Y, Yang D H. Fibrinolytic activity in end-stage renal disease. Nephron 1993; 63: 188-192.
276. Brown P A, Wilson H M, Reid FJ, et al. Urokinase-plasminogen activator is synthesized in vitro by human glomerular epithelial cells but not by mesangial cells. Kidney Int 1994; 45: 43-47.
277. Heussen-Schemmer C, Barron J R, Swanepoel C R, Dowdle E B. Urinary tissue plasminogen activator in renal disease. Nephron 1993; 64: 42-44.
278. Kaizu K, Uriu K, Eto S. Role of intrarenal coagulation and anticoagulant therapy in the progression of diabetic nephropathy. Nippon Jinzo Gakkai Shi 1993; 35: 35-42.
279. Suzuki S, Sato H, Shimada H, et al. Significance of glomerular deposition of plasmin-alpha 2-plasmin inhibitor complexes in various glomerulopathies. ClinNephrol 1993; 40: 270-276.
280. Mulder G, Jones R, Cederholm-Williams S, Cherry G, Ryan T. Fibrin cuff lysis in chronic venous ulcers treated with a hydrocolloid dressing. Int J Dermatol 1993; 32: 304-306.
281. Gertner E, Lie J T. Systemic therapy with fibrinolytic agents and heparin for recalcitrant nonhealing cutaneous ulcer in the antiphospholipid syndrome. J Rheumatol 1994; 21: 2159-2161.
282. Veraart J C J M, Hamalyuk K, Neumann HAM, Engelen J. Increased plasma activity of plasminogen activator inhibitor 1 (PAI-1) in two patients with Klinefelter's syndrome complicated by leg ulcers. BrJDermatol 1994; 130: 641-644.
283. Ibbotson S H, Layton A M, Davies J A, Goodfield M J D. Plasminogen activator inhibitor 1 (PAI-1) levels in patients with chronic venous leg ulcération (letter). BrJDermatol 1994; 131: 738.
284. Vanscheidt W, Kresse O, Hach-Wunderle V, et al. Leg ulcer patients: no decreased fibrinolytic response but white cell trapping after venous occlusion of the upper limb. Phlebology 1992; 7: 92-96.
285. Hitchcock M G, Pizzo S V. Fibrinolytic defects in the cutaneous vasculitis atrophie blanche. In: Glas-Greenwalt P, ed. Fibrinolysis in disease, Vol 1. Boca Raton: CRC Press, 1995: 264-267.
286. Rosenfeld B A, Beattie C, Christopherson R, et al. The effects of different anesthetic regimens on fibrinolysis and the development of postoperative arterial thrombosis. Anesthesiology 1993; 79: 435-443.
287. Gelman S. General versus regional anesthesia for peripheral vascular surgery. Is the problem solved? Anesthesiology 1993; 79:415-418.
288. Lang I M, Marsh J J, Olman M A, et al. Expression of type 1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-2721.
289. DeclerckPJ, Juhan-Vague I, Felez J, Wiman B. Pathophysiology of fibrinolysis. J Int Med 1995; 236: 425-432.
290. Hamsten A. Haemostatic function and coronary artery disease. NewEnglJMed 1995; 332: 677-678.
291. Rabbani L E, Loscalzo J. Recent observations on the role of hemostatic determinants in the development of the atherothrombotic plaque. Atherosclerosis 1994; 105: 1-7.
292. Jansson J H, Olofsson B O, Nilsson T K. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up. Circulation 1993; 88: 2030-2034.
293. Ridker P M, Vaughan D E, Stampfer M J, Manson J E, Hennekens C H. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993; 341: 1165-1168.
294. Thompson S G, Kienast J, Pyke S D M, et al. Hemostatic factors and the risk of myocardial infarction and sudden death in patients with angina pectoris. New Engl J Med 1995; 332: 635-641.
295. Juhan-Vague I, Chandler W L, Aillaud M F, et al. Humans clear tPA faster than tPA/PAI-1 complex (abstract). Fibrinolysis 1996b; 10, suppl S: 102.
296. Jansson J H, Nilsson T K, Johnson O. Von Willebrand factor in plasma: a new risk factor for recurrent myocardial infarction and death. BrMedJ 1991; 66: 351-355.
297. Nilsson T K, Boman K, Bjerle P, Hallmans G, Hellsten G. Von Willebrand factor and fibrinolytic variables are differently affected in the insulin resistance syndrome. J Intern Med 1994; 235:419-423.
298. Glueck C J, Rorick M H, Schmerler M, et al. Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125:319-325.
299. Lindgren A, Lindoff C, Norrving B, Astedt B, Johansson B B. Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients. Stroke 1996; 27: 1066-1071.
300. Maragglione M, Di Minno G, Grandome E, et al. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischémie stroke. Arterioscler Thromb 1994; 14: 1741-1745.
301. Ridker P M, Hennekens C H, Stampfer M J, Manson J E, Vaughan D E. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943.
302. Kooistra T, Lansink M, Emeis JJ. Stimulators of tissue-type plasminogen activator. In: Drugs of the future. Drugs of the Future 1996; 21: 291-299.